290 related articles for article (PubMed ID: 30726782)
61. Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome.
Gupta R; Abdalla SH; Bain BJ
Leuk Lymphoma; 1999 Aug; 34(5-6):615-9. PubMed ID: 10492088
[TBL] [Abstract][Full Text] [Related]
62. Causes and Pathophysiology of Acquired Sideroblastic Anemia.
Rodriguez-Sevilla JJ; Calvo X; Arenillas L
Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140729
[TBL] [Abstract][Full Text] [Related]
63. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.
Bonnet S; Carillo S; Legrand B; Burroni B; Lavabre-Bertrand T; Requirand G; Robert N; Fornero L; Al Mansoori A; Moreaux J; Cartron G; Gabellier L; Herbaux C
Eur J Haematol; 2024 Mar; 112(3):475-478. PubMed ID: 37918825
[TBL] [Abstract][Full Text] [Related]
64. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
65. Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
Schwaab J; Ernst T; Erben P; Rinke J; Schnittger S; Ströbel P; Metzgeroth G; Mossner M; Haferlach T; Cross NC; Hochhaus A; Hofmann WK; Reiter A
Ann Hematol; 2012 Nov; 91(11):1713-20. PubMed ID: 23010802
[TBL] [Abstract][Full Text] [Related]
66. Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.
Hochman MJ; Savani BN; Jain T
EJHaem; 2021 Aug; 2(3):607-615. PubMed ID: 35844680
[TBL] [Abstract][Full Text] [Related]
67. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
68. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
Gattermann N; Billiet J; Kronenwett R; Zipperer E; Germing U; Nollet F; Criel A; Selleslag D
Blood; 2007 Feb; 109(3):1334-5. PubMed ID: 17244688
[No Abstract] [Full Text] [Related]
69. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
[TBL] [Abstract][Full Text] [Related]
70. MDS/MPN with ring sideroblasts and thrombocytosis masquerading as prefibrotic/early primary myelofibrosis.
Xu Z
Blood; 2017 Feb; 129(5):657. PubMed ID: 28153839
[No Abstract] [Full Text] [Related]
71. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
[TBL] [Abstract][Full Text] [Related]
72. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
73. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.
Ochi T; Fujiwara T; Ono K; Suzuki C; Nikaido M; Inoue D; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Nakamura Y; Harigae H
Sci Rep; 2022 Aug; 12(1):14562. PubMed ID: 36028755
[TBL] [Abstract][Full Text] [Related]
74. Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease.
Pérez Sánchez I; Pérez Corrala A; Menarguez Palanca J; Mayayo Crespo M; Escudero Soto A; Pintado Cros T
Leuk Lymphoma; 2003 Mar; 44(3):557-9. PubMed ID: 12688334
[TBL] [Abstract][Full Text] [Related]
75. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
Zoi K; Cross NC
Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
[TBL] [Abstract][Full Text] [Related]
76. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.
Gerds AT
Curr Hematol Malig Rep; 2014 Dec; 9(4):400-6. PubMed ID: 25195196
[TBL] [Abstract][Full Text] [Related]
77. A man with polycythemia vera, myelodysplastic syndrome and acquired microcytosis.
Mann M; Kreuzbauer T; Sykes DB
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31413051
[TBL] [Abstract][Full Text] [Related]
78. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
79. A Young Woman with Thrombocytosis.
Bose P
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S14-S17. PubMed ID: 32862851
[TBL] [Abstract][Full Text] [Related]
80. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
Visconte V; Tabarroki A; Zhang L; Parker Y; Hasrouni E; Mahfouz R; Isono K; Koseki H; Sekeres MA; Saunthararajah Y; Barnard J; Lindner D; Rogers HJ; Tiu RV
J Hematol Oncol; 2014 Dec; 7():89. PubMed ID: 25481243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
